TESTING AND RELEASE STRATEGIES FOR MINITABLETS



Jun2019 Asha Rajapakshe

Public

What is a Minitablet?



Minitablets with (from top to bottom) four, three, and two millimeter diameters, pictured with a U.S. penny to illustrate their sizes

Rumondor, Alfred et al. "Minitablets: Manufacturing, Characterization Methods, and Future Opportunities". *American Pharmaceutical Review*. July 30, 2016

The term "*minitablets*" commonly refers to compressed tablets with size smaller than typical tablets.

"Granules, Oral Granules, Sprinkles, Micro tablets"

- No regulatory guidelines that define minitablets, the term has been used to describe tablets with diameters between one to four millimeters (mm).
- Oral dosage forms smaller than 2.5 mm → oral granules
 - Many minitablet products are focused at this size range, to take advantage of the potential flexibility in dosage form administration (e.g. mixed with soft foods).



Few Examples of Minitablet Products

| Product | Company | Molecule | Indication | Product presentation |
|---|----------|---------------|----------------------------------|---|
| Kalydeco® | Vertex | Ivacaflor | Cystic fibrosis | ~2 mm mini-tablets in stick pack |
| Lamisil® | Novartis | Terbinafine | Antifungal | ~2 mm mini-tablets in stick pack |
| Orifil Long® | Desitin | Valproate | Epilepsy | ~2 mm mini-tablets in capsules and stick pack |
| Levetiracetam Desitin® | Desitin | Levetiracetam | Epilepsy | ~2 mm mini-tablets in stick pack |
| Pancrease® MT10/MT20 | McNEIL | Pancrelipase | Pancreatitis, cystic fibrosis | ~2 mm mini-tablets in capsules |
| Image: Statistic Statis Statis Statistic Statistic Statistic Statistic Stat | | | Pancreas MT 10 McNEL | Pancree MT 21 IcNEIL |



Opportunities Offered by Minitablets

Compliance

- Accurate and flexible dosing -> Reduce discards!
- Reduce user errors
- Less complicated human factor studies

Patient Friendly and Personalized Medicine

- Palatability (Easy to swallow and enhance palatability when mixed with food and drink
- Dose flexibility, unit dose options
- Multiple dose unit options which can combine different release kinetics/API

Production & Stability

- Utilize standard tablet presses/multiple-tip tooling , Coated or uncoated minitablets
- Ability to separate API interactions and increase palatability
- Various product presentations: Ease of capsule or sachet filling or desiccated bottles



Challenges Offered by Minitablets





Traditional vs Minitablet Batches?





One/two final product image



Why Not Traditional Testing?

Goal is to demonstrate product quality

Traditional testing = Repeat testing

- Repeat testing (e.g same granule batch in different capsule batches)
 - Analytical testing and quality release burden on several small scale batches (significantly higher numbers of tests)
 - Utilizing a significant portion of the batch just for analytical testing

Increased supply chain flexibility-Lower volumes, Personalized medicine

- Make-to-order for final step:
 - Faster turnaround from demand to delivery
 - Unclear forecasts
 - Image proliferation

Bulk minitablets can be counted!

Many CQAs determined by the compression/coating steps



Collect industry/regulatory input on efficient product release for minitablets/granules by conducting testing at the right stage to ensure product quality

CASE STUDY

Product: IR oral granule –Single entity product

Dosage form: Capsules intended for sprinkling(could be stick packs/sachets too)

Quality attributes: Identity, Content uniformity, Assay and Degradation products, Dissolution, Water activity, Microbial limits

Terminology used here:

- Oral granules = minitablets
- Bulk minitablets = coated/uncoated minitablets prior to encapsulation
- Unit dose = minitablets in capsules with varying counts based on the dose.
 - Lowest dose = 10 count
 - Highest dose = 100 count



Example Manufacturing Steps





RELEASE & SPECIFICATION



3 Possible Approaches

- 1. Conduct release testing only after encapsulation- no testing of bulk minitablets
- 2. Conduct testing at bulk minitablet step AND for each unit dose after encapsulation
- 3. Hybrid approach:
 - a) Conduct tests on bulk minitablets for
 CQAs that are not impacted by
 encapsulation step.
 - b) Limited tests at minitablets in capsules



THANK YOU



